Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Solid Tumors × Tiragolumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 6 Squamous Cell Carcinoma of Head and Neck 2 Melanoma 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Squamous Cell 2 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Spinocerebellar Degenerations 1 Solid Tumors 1 Solid Tumor, Adult 1 Small Cell Lung Carcinoma 1 Rectal Neoplasms 1 PD-L1-selected Solid Tumors 1 Neoplasms 1 Lung Neoplasms 1 Glioblastoma 1 Carcinoma, Renal Cell 1 Carcinoma 1 Breast Neoplasms 1 Brain Neoplasms 1 Advanced Rare Malignant Solid Neoplasm 1

Interventions

atezolizumab 3 Docetaxel 3 pembrolizumab 2 olaparib 2 lenvatinib 2 Leucovorin 2 Irinotecan 2 Immune Checkpoint Inhibitors 2 Fluorouracil 2 Filgrastim 2 Capecitabine 2 zolbetuximab 1 tomivosertib 1 spartalizumab 1 somatostatin receptor 2 1 pralsetinib 1 pegylated granulocyte colony-stimulating factor 1 necitumumab 1 motesanib diphosphate 1 ipatasertib 1 inavolisib 1 entrectinib 1 ensartinib 1 dapagliflozin 1 cobimetinib 1 cemiplimab 1 cat's claw extract 1 balugrastim 1 anlotinib 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06331598 2024-12-24

IMperator

Hoffmann-La Roche

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡